Cargando…
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma
OBJECTIVE: Multiple therapeutic agents exist for advanced hepatocellular carcinoma (HCC), but prognostic factors in second-line and subsequent therapies are unclear. Ramucirumab is a molecular-targeted agent effective against hepatocytes with alpha-fetoprotein (AFP) >400 ng/mL after sorafenib fai...
Autores principales: | Sugimoto, Rie, Motomura, Kenta, Ooho, Aritsune, Aratake, Yoshifusa, Ueda, Akihiro, Senju, Takeshi, Tanaka, Yuki, Yada, Masayoshi, Tanaka, Kohsuke, Kuwano, Akifumi, Morita, Yuusuke, Nagasawa, Shigehiro, Ooe, Mari, Mutsuki, Taiji, Yoshimoto, Tsuyoshi, Yamashita, Naoki, Nakashima, Mai, Hioki, Tomonobu, Koyanagi, Toshimasa, Higuchi, Nobito, Nakamura, Tsukasa, Harada, Shigeru, Tanaka, Masatake, Tada, Seiya, Satoh, Takeaki, Uchimura, Koutarou, Kuniyoshi, Masami, Nakamuta, Makoto, Kohjima, Motoyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683807/ https://www.ncbi.nlm.nih.gov/pubmed/36328582 http://dx.doi.org/10.2169/internalmedicine.9237-21 |
Ejemplares similares
-
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
por: Sugimoto, Rie, et al.
Publicado: (2022) -
Acute kidney injury is an unfavorable prognostic factor in acute liver failure and is associated with tumor necrosis factor-alpha
por: Imoto, Koji, et al.
Publicado: (2023) -
NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells
por: Kohjima, Motoyuki, et al.
Publicado: (2007) -
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients
por: Imoto, Koji, et al.
Publicado: (2019) -
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)